Climb Bio, Inc.
Clinical trials sponsored by Climb Bio, Inc., explained in plain language.
-
New antibody targets rare kidney disease
Disease control Recruiting nowThis study is testing an experimental antibody called budoprutug in adults with primary membranous nephropathy, a rare autoimmune kidney disease. Researchers want to see if the treatment is safe and can help reduce kidney damage by targeting specific immune cells. About 45 partic…
Phase: PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New lupus drug targets immune system in early human trial
Disease control Recruiting nowThis is an early safety study of an experimental drug called budoprutug for adults with active systemic lupus erythematosus (SLE). The main goal is to see if different single doses are safe and well-tolerated in about 30 participants whose lupus hasn't responded well to standard …
Phase: PHASE1 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:42 UTC
-
New antibody tested for rare bleeding disorder
Disease control Recruiting nowThis early-stage study is testing a new antibody drug called budoprutug in adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The main goal is to check if the drug is safe and well-tolerated, while also seeing if it helps raise plate…
Phase: PHASE1, PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC
-
First humans receive experimental antibody in early safety test
Knowledge-focused Recruiting nowThis is the first time a new antibody drug called CLYM116 is being tested in people. The main goal is to check if it is safe and how the body processes it. The study will involve up to 48 healthy volunteers who will receive injections of the drug or a placebo. Researchers will mo…
Phase: PHASE1 • Sponsor: Climb Bio, Inc. • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:25 UTC